The staging and assessment of moderate to severe Alzheimer disease

被引:63
作者
Feldman, HH [1 ]
Woodward, M
机构
[1] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[2] Austin Hlth, Dept Aged Care, Heidelberg, Vic, Australia
关键词
D O I
10.1212/WNL.65.6_suppl_3.S10
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Alzheimer disease (AD) and its stages are clinically defined by the patterns of gradual and progressive decline in cognition and in functional ability with accompanying neuropsychiatric symptoms. The moderate to severe AD (MSAD) stages are particularly important both for their prevalence and for the transitions that occur at these stages. In MSAD, cognitive losses accelerate, neuropsychiatric symptoms increase, and functional autonomy is lost. There is increasing burden on caregivers, who report poorer self-rated health, increased depressive symptoms, and more use of psychoactive medications. The neurologic care of MSAD demands both skilled assessment and management. Beyond the cognitive and neurobehavioral symptom complex in MSAD, a range of other issues also emerge, including gait and movement disorders, nutritional problems, and incontinence. This review addresses the symptoms and staging of AD and emphasizes the key management issues.
引用
收藏
页码:S10 / S17
页数:8
相关论文
共 101 条
[81]   Goal setting and attainment in Alzheimer's disease patients treated with donepezil [J].
Rockwood, K ;
Graham, JE ;
Fay, S .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 73 (05) :500-507
[82]   A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease [J].
Rogers, SL ;
Farlow, MR ;
Doody, RS ;
Mohs, R ;
Friedhoff, LT ;
Albala, B ;
Baumel, B ;
Booker, G ;
Dexter, J ;
Farmer, M ;
Feighner, JP ;
Ferris, S ;
Gordon, B ;
Gorman, DG ;
Hanna, G ;
Harrell, LE ;
Hubbard, R ;
Kennedy, J ;
McCarthy, J ;
Scharre, DW ;
Schaerf, F ;
Schneider, L ;
Seltzer, B ;
Siegal, A ;
Stark, SR ;
Strauss, A ;
Walshe, TM .
NEUROLOGY, 1998, 50 (01) :136-145
[83]  
ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356
[84]   Efficacy and safety of rivastigmine in patients with Alzheimer's disease:: international randomised controlled trial [J].
Rösler, M ;
Anand, R ;
Cicin-Sain, A ;
Gauthier, S ;
Agid, Y ;
Dal-Bianco, P ;
Stähelin, HB ;
Hartman, R ;
Gharabawi, M .
BMJ-BRITISH MEDICAL JOURNAL, 1999, 318 (7184) :633-638
[85]   Progressive frontal gait disturbance with atypical Alzheimer's disease and corticobasal degeneration [J].
Rossor, MN ;
Tyrrell, PJ ;
Warrington, EK ;
Thompson, PD ;
Marsden, CD ;
Lantos, P .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 67 (03) :345-352
[86]  
Saxton J., 1990, PSYCHOL ASSESSMENT, V2, P298, DOI DOI 10.1037/1040-3590.2.3.298
[87]   Recent developments in pain in dementia [J].
Scherder, E ;
Oosterman, J ;
Swaab, D ;
Herr, K ;
Ooms, M ;
Ribbe, M ;
Sergeant, J ;
Pickering, G ;
Benedetti, F .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7489) :461-464A
[88]  
Schmitt FA, 1997, ALZ DIS ASSOC DIS, V11, pS51
[89]  
Schneider LS, 1997, ALZ DIS ASSOC DIS, V11, pS22
[90]   Linguistic ability in early life and cognitive function and Alzheimer's disease in late life - Findings from the Nun Study [J].
Snowdon, DA ;
Kemper, SJ ;
Mortimer, JA ;
Greiner, LH ;
Wekstein, DR ;
Markesbery, WR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (07) :528-532